May 13, 2024 10:41 AM EDT

Deciphera had another bidder before Ono deal; Bristol Myers reports Ph3 fail in lung cancer

ENDPOINTS

Plus, news about OnKure:

Deciphera’s other bidder: Before its acquisition by Ono Pharmaceutical, Deciphera had one other bidder that offered $19.00 per share, according to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Deciphera had another bidder before Ono deal; Bristol Myers reports Ph3 fail in lung cancer

ENDPOINTS

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

De­ci­phera had an­oth­er bid­der be­fore Ono deal; Bris­tol My­ers re­ports Ph3 fail in lung can­cer

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Deciphera had another bidder before Ono deal; Bristol Myers reports Ph3 fail in lung cancer